Sign in

REGENERON PHARMACEUTICALS, INC.

REGN

Share price not shown yet: live market data is not connected. Everything below comes from REGN’s own SEC filings.

View options chain →

Fundamentals

SEC filings

Ratios that need a share price (P/E, PEG, P/S, dividend yield) are not shown yet, because live market data is not connected. Everything below comes from filed financials.

Rule of 40
33%
rev growth + FCF margin
Revenue growth
+9.3%
TTM vs prior TTM
FCF margin
24.2%
ROE (TTM)
14.0%
TTM NI ÷ avg equity
Net debt
-$6.0B
total debt − cash & ST inv.
Dilution (YoY)
-2.4%
negative = buybacks
SBC / revenue
6.4%
TTM revenue
$15.5B

Revenue

$0B$1B$2B$3B$4B$5BDec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’26$4B

EPS (diluted)

$0.00$5.00$10.00$15.00$20.00Dec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’26$12.23

Operating

20%30%40%50%Dec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’2630%

Net income

$0.0B$0.5B$1.0B$1.5B$2.0BDec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’26$1.3B

Net margin

20%30%40%Dec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’2630%

Free cash flow vs. stock-based comp

FCFSBC
$0B$1B$2B$3BDec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’26$1B

Operating cash flow vs. capex

OCFCapex
$0B$1B$2B$3BDec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’26$1B

R&D vs. SG&A

R&DSG&A
$0.0B$0.5B$1.0B$1.5BDec ’21Sep ’22Jun ’23Mar ’24Dec ’24Sep ’25Jun ’26$1.6B

Insider activity

SEC Form 4
Reading Form 4 filings from SEC EDGAR…